JP2011524850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524850A5 JP2011524850A5 JP2010543182A JP2010543182A JP2011524850A5 JP 2011524850 A5 JP2011524850 A5 JP 2011524850A5 JP 2010543182 A JP2010543182 A JP 2010543182A JP 2010543182 A JP2010543182 A JP 2010543182A JP 2011524850 A5 JP2011524850 A5 JP 2011524850A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutically acceptable
- acceptable salt
- depression
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 12
- 208000019901 Anxiety disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 229960004606 clomipramine Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 2
- 229960005426 doxepin Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960004801 imipramine Drugs 0.000 claims 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 150000003512 tertiary amines Chemical class 0.000 claims 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 | |
| US61/039,121 | 2008-03-25 | ||
| PCT/US2009/030811 WO2009094260A1 (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524850A JP2011524850A (ja) | 2011-09-08 |
| JP2011524850A5 true JP2011524850A5 (enExample) | 2012-02-23 |
| JP5345637B2 JP5345637B2 (ja) | 2013-11-20 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543182A Active JP5345637B2 (ja) | 2008-01-22 | 2009-01-13 | κ選択的オピオイド受容体アンタゴニスト |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422369B (zh) * | 2008-01-22 | 2014-01-11 | Lilly Co Eli | κ選擇性類鴉片受體拮抗劑 |
| KR20100130596A (ko) * | 2008-01-22 | 2010-12-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 부신 피질 자극 호르몬 방출 인자 길항 작용을 갖는 3 환식 화합물 및 이를 함유하는 약학 조성물 |
| WO2013040321A1 (en) | 2011-09-15 | 2013-03-21 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
| WO2013042054A1 (en) | 2011-09-19 | 2013-03-28 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| CA2858752C (en) | 2011-12-09 | 2019-12-31 | Research Triangle Institute | 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| JP2016519161A (ja) * | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| EP3596069B1 (en) | 2017-03-17 | 2022-07-13 | The Scripps Research Institute | Kappa opioid receptor antagonists and products and methods related thereto |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| JP2024516297A (ja) | 2021-05-04 | 2024-04-12 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のための組成物及び方法 |
| MX2024008618A (es) * | 2022-01-10 | 2024-09-25 | Janssen Pharmaceuticals Inc | Composiciones y métodos para el tratamiento de la depresión. |
| JP2025503649A (ja) * | 2022-01-10 | 2025-02-04 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のための組成物及び方法 |
| EP4489748A1 (en) * | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| JP2025508069A (ja) * | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | アチカプラントを含む組成物 |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) * | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| EP1178990B1 (en) * | 1999-05-12 | 2003-01-29 | F. Hoffmann-La Roche Ag | Imidazodiazepine derivative |
| EP1337859A1 (en) * | 2000-10-05 | 2003-08-27 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| WO2002049643A1 (en) * | 2000-12-21 | 2002-06-27 | The Mclean Hospital Corporation | Treatment of depression |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| BR0308918A (pt) * | 2002-03-28 | 2005-01-04 | Wisys Technology Found Inc | Agentes ansiolìticos com efeitos sedativos e atáxicos reduzidos |
| PL212616B1 (pl) * | 2002-09-19 | 2012-10-31 | Lilly Co Eli | Eter diarylowy i kompozycja farmaceutyczna zawierajaca ten eter |
| BRPI0407616A (pt) | 2003-03-07 | 2006-02-14 | Lilly Co Eli | composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" |
| WO2004080996A1 (en) * | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | Opioid receptor antagonists |
| JP2007516256A (ja) * | 2003-12-12 | 2007-06-21 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
| CN1894240A (zh) * | 2003-12-22 | 2007-01-10 | 伊莱利利公司 | 阿片受体拮抗剂 |
| US7381750B2 (en) * | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
| ATE399164T1 (de) * | 2004-03-12 | 2008-07-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| AU2005222640A1 (en) * | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| ES2318472T3 (es) * | 2004-03-15 | 2009-05-01 | Eli Lilly And Company | Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad. |
| CA2557794A1 (en) * | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| US8551986B2 (en) * | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| CA2646899C (en) | 2006-04-04 | 2014-05-06 | Holger Lars Hermann | Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders |
| JP5362565B2 (ja) | 2006-08-09 | 2013-12-11 | スミスクライン ビーチャム コーポレーション | オピオイド受容体のアンタゴニストまたはインバースアゴニストである新規化合物 |
| US20100222345A1 (en) | 2006-08-09 | 2010-09-02 | Caroline Jean Diaz | Novel compounds as antagonists or inverse agonists for opioid receptors |
| KR20090051778A (ko) | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| TWI422369B (zh) * | 2008-01-22 | 2014-01-11 | Lilly Co Eli | κ選擇性類鴉片受體拮抗劑 |
-
2009
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524850A5 (enExample) | ||
| CA2713025A1 (en) | Kappa selective opioid receptor antagonist | |
| JP2010529118A5 (enExample) | ||
| NZ598083A (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| JP2011037901A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| JP2010513478A5 (enExample) | ||
| PL2142193T3 (pl) | 1-[2-(2,4-demetylofenylosulfanylo)fenylo]piperazyna jako związek z połączonym wychwytem zwrotnym serotoniny, aktywnością względem 5HT3 i 5-HT1A do leczenia bólu lub rezydualnych objawów depresji związanych ze snem i procesami poznawczymi | |
| IL205872A (en) | Process for the preparation of compounds 2- [4- (3- or 2-fluorobenzyloxy) benzylamino] high-purity propanamide, medicinal preparations containing them, and their use in the preparation of drugs | |
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| JP2012532874A5 (enExample) | ||
| CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
| JP2009541443A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2011148799A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
| JP2008539268A5 (enExample) | ||
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2015500223A5 (enExample) | ||
| JP2012504560A5 (enExample) | ||
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| GEP20166488B (en) | Co-crystals and salts of ccr3-inhibitors | |
| RU2015111836A (ru) | Производные триазолкарбоксамида |